Table 4. Deleobuvir susceptibility of novel NS5B variants from patient isolates.

Patient	HCV GT	NS5B variant at rebound	Deleobuvir EC50
			Baseline NS5B (nM)	NS5B at rebound (nM)	Fold shifta
A	1b	A421T	37	72	1.9
B	1a	A421V+P495L	97	6367	66b
C	1a	P495L	7.5	917	122
		A421V+P495L		2267	302

Data from SOUND-C2.

^aFold shift in EC₅₀ relative to baseline.

^bNote higher EC₅₀ initially at baseline.

EC₅₀, 50% effective concentration; GT, genotype; HCV, hepatitis C virus.